Liyi Jia - Merck Res Labs, Merck & Co Inc

基本信息

Career Trajectory

Bio

No content for now

Research Interests

Papers共 18 篇Author StatisticsCo-AuthorSimilar Experts

By YearBy Citation主题筛选期刊级别筛选合作者筛选合作机构筛选

Abstract GS01-02: Phase 3 Study of Neoadjuvant Pembrolizumab or Placebo Plus Chemotherapy, Followed by Adjuvant Pembrolizumab or Placebo Plus Endocrine Therapy for Early-Stage High-Risk ER+/HER2− Breast Cancer: KEYNOTE-756

Cancer Researchno. 9_Supplement (2024): GS01-02

Cited0Views0Bibtex

LBA21 KEYNOTE-756: Phase III Study of Neoadjuvant Pembrolizumab (pembro) or Placebo (pbo) + Chemotherapy (chemo), Followed by Adjuvant Pembro or Pbo + Endocrine Therapy (ET) for Early-Stage High-Risk ER+/HER2– Breast Cancer

F. Cardoso,H.L. McArthur,P. Schmid, J. Cortés,N. Harbeck,M.L. Telli,D.W. Cescon,J. O'Shaughnessy,P. Fasching, Z. Shao,D. Loirat,Y.H. Park,M.E. González Fernández,Z. Liu,H. Yasojima, Y. Ding,L. Jia, V.V. Karantza, K.E. Tryfonidis,A. Bardia

Annals of Oncology (2023): S1260-S1261

Cited0Views0Bibtex

Author Statistics

Co-Author

Co-Institution

D-Core

合作者
学生
导师

No result temporarily, you can search similar Scholar with the same research interest

Data Disclaimer

The page data are from open Internet sources, cooperative publishers and automatic analysis results through AI technology. We do not make any commitments and guarantees for the validity, accuracy, correctness, reliability, completeness and timeliness of the page data. If you have any questions, please contact us by email: report@aminer.cn